bio shares dated 26/8/11, page-10

Thanks for the replies guttergripper and hector31. The single blinding is not a major concern but the CT administrators and physicians COULD be selective about the active / control groups based on patients they believe may be more conducive to providing more significant improvement. The randomised, double blind, placebo controlled trials remove most possible influences which is why when possible they are generally required by reg. bodies in phase 3 and which is one of several reasons that makes phase 3 the most risky. I have followed several companies that have fallen at the final hurdle and probably just being a little over cautious. I certainly agree that one positive phase 3 result will add enormous credibility to the entire pipeline and this is why i'm watching this stock with interest.